Human epidermal growth factor receptor (HER 2)/neu expression and gene amplification in colorectal cancer

African Journal of Biotechnology

Volumn 10, Issue 74, 2011, Pages 16732-16739

  Deng, Wei ^a   Dong, Wei Guo ^a   Zhan, Na ^a   Liao, Fei ^a   Wu, Hong xue ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Colorectal cancer; Fluorescence in situ hybridization; HER 2 neu; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL FEATURE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TUMOR DIFFERENTIATION;

EID: 82155164669     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: 10.5897/AJB11.2397     Document Type: Article

References (35)

1. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986). The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 232: 1644-1646.
2. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, Sanea NA, Al-Dayel F, Al-Mana (2007). HER2, TOP2A, CCND1, EGFR and CMYC oncogene amplification in colorectal cancer. J Clin Pathol. 60: 768-772.
3. Arnould L, Arveux P, Couturier J, Gelly-Marty M, Loustalot C, Ettore F, Sagan C, Antoine M, Penault-Llorca F, Vasseur B, Fumoleau P, Coudert BP (2007). Pathologic complete response to trastuzumabbased neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res. 13: 6404-6409.
4. Beahrs OH (1992). Staging of cancer of the colon and rectum. Cancder. 70: 1393-1396.
5. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR (2005). Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive nonsmall-cell lung cancer patients. J Clin Oncol.23: 5007-5018.
6. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Sseeburg PH, Libermann TA, Schlessinger J, Franckc U (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230: 1132-1139.
7. Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C, Modjtahedi H (2006). Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol. 28: 329-335.
8. Essapen S, Thomas H, Green M, De Veries C, Cook MG, Marks C, Topham C, Modjtahedi H (2004). The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol. 24: 241-248.
9. Field AS, Chamberlain NL, Tran D, Morey AL (2001). Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridisation. Pathology, 33: 278-282.
10. Giannopoulou E, Antonacopoulou A, Floratou K, Papavassiliou AG, Kalofonos HP (2009), Dual targeting of EGFR and HER-2 in colon cancer cell lines. Cancer Chemother Pharmacol. 63: 973-998.
11. Goldenberg MM (1999). Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 21: 309-318.
12. Gullo G, Bettio D, Torri V, Masci G, Salvini P, Santoro A (2009). Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer. Invest New Drugs. 27: 179-183.
13. Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA (2004). HER-2 receptor expression, location, and activation in colorectal cancer cell lines and human tumors. Int. J. Cancer. 108: 540-548.
14. Hartmann A, Blaszyk H, Tsushima K, Tamura Y, Cunningham JM, McGovern RM, Schroeder JJ, Sommer SS, Kovach JS (1996). High frequency of P53 mutation in primary breast cancers in Japanese women, a low-incidence population. Br J Cancer. 73: 896-901.
15. Hartmann A, Rosanelli G, Blaszyk H, Cunningham JM, McGovern RM, Schroeder JJ, Schaid D, Kovach JS, Sommer SS (1995). Novel pattern of P53 mutation in breast cancers from Austrian woman. J Clin Invest. 95: 686-689.
16. Jemal A, Bray F, Melissa M, Ferlay J, Ward E, Forman D (2011). Global cancer statistics. CA Cancer J. Clin. 61: 69-90.
17. Kapitanovic S, Radosevic S, Kapitanovic M (1997). The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 112: 1103-1113.
18. Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, Bennani F, Eustace PW, Tobbia I (2009). Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer. 9: 1.
19. Kluftinger AM, Robinson BW, Quenville NF, Finley RJ, Davis NL (1992). Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol. 1: 97-105.
20. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Löhrs U (2001). Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol.19: 354-363.
21. Marx AH, Burandt EC, Choschzick M, Simon R (2010). Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Human Pathology, 41: 1577-1585.
22. Marx AH, Tharun L Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G (2009). HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 40: 769-777.
23. Nathanson DR, Culliford AT, Shia J, Chen B, D'Alessio M, Zeng ZS (2003). HER 2/neu expression and gene amplification in colon cancer. Int. J. Cancer. 105: 796-802.
24. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y (2004). Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol. 17: 895-904.
25. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M (1998). Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology, 55: 548-555.
26. Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Han WK Kim H (2007). HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int. J. Colorectal Dis. 22: 491-497.
27. Pauletti G, Godolphin W, Press MF, Slamon DJ (1996). Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene.13: 63-72.
28. Press MF, Bernstein L, Thomas PA, Thomas PA (1997). HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 15: 2894-2904.
29. Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, Chen HX, Finkelstein S (2004). Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 22: 858-865.
30. Reichelt U, Duesedau P, Tsourlakis MC, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, Sauter G (2007). Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 20: 120-129.
31. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987). Human breast cancer:correlation of relapse and survival with amplification of the HER-2 neu oncogene. Science, 235: 177-182.
32. Steele RJ, Kelly P, Ellul B, Eremin O (1990). Epidermal growth factor receptor expression in colorectal cancer. Br J Surg. 77: 1352-1354.
33. Tannapfel A, Kuhn R, Kepler H, Wittekind Ch (1996). Expression of cerbB2 oncogene product in different tumours and its standardized evaluation. Anal Cell Pathol.10: 149-160.
34. Tapia C, Glatz K, Novotny H, Lugli A, Horcic M, Seemayer CA, Tornillo L, Terracciano L, Spichtin H, Mirlacher M, Simon R, Sauter G (2007). Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol. 20: 192-198.
35. Tsuda H (2006). HER-2 (c-erbB-2) test update: present status and problems. Br Cance.13: 236-248.